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Campylobacter jejuni enteritis is the most frequently
identified infection preceding the Guillain-Barré syndrome
(GBS) and neural damage is thought to be induced through
molecular mimicry between C. jejuni lipo-oligosaccharide
(LOS) and human gangliosides [1]. It has been questioned
whether or not other Campylobacter species, including C.
curvus, C. upsaliensis and C. coli, could be similarly
involved [2–4]. This is relevant because it would imply that
bacterial factors considered important in the aetiology of
GBS crossed species barriers. Two prior reports have
appeared where C. coli was putatively associated with a
case of GBS [2, 3].
We here present two female patients with GBS, one from
the Netherlands (patient GB50) and one from France
(patient 664H2004). From a faecal specimen obtained for
both patients, a C. coli strain was isolated. On the basis of
surface protein profiling, the strains were unequivocally
demonstrated to belong to the species C. coli (results not
shown). The strains were encoded GB50 and 664H2004,
respectively, and stored at −80°C. For patient GB50, a
serum sample obtained at the acute GBS phase was
available. This sample was also stored at −80°C.
Strains were grown on Mueller-Hinton agar at 37°C for
48 h, after which DNA was extracted, as described by
Pitcher et al. [5]. Amplified fragment length polymorphism
(AFLP) analysis was performed, as described by Duim
et al. [6]. In brief, 1 µg of genomic DNAwas digested with
the HindIII-HhaI restriction enzyme combination and site-
specific adaptors were ligated to the restriction fragments.
Primers complementary to the adaptor and restriction site
sequence were used in pre-selective and selective polymerase
chain reaction (PCR) amplifications. The amplified and
fluorescently labelled fragments were loaded on an ABI
Prism 377 automated sequencer. GeneScan version 3.1
(Applied Biosystems) was used for data collection, and the
AFLP profiles were imported, using the CrvConv filter, in
BioNumerics 4.61 (Applied Maths, Belgium) for normal-
isation and further analysis. The obtained AFLP profiles were
included in an in-house AFLP reference frame, containing
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profiles from all known Campylobacter species. Similarity
between the normalised fingerprints was determined by the
Pearson product moment correlation coefficient and a
UPGMA dendrogram was constructed. The profiles from
both isolates clearly formed a cluster together with C. coli
reference strains (Fig. 1).
Using LOS gene cluster-specific PCR tests, the 664H2004
strain was demonstrated to harbour a B-type gene cluster [7].
For GB50, neither the cst2 nor the cgtA gene was shown to
be present. This convincingly demonstrates that this strain
does not harbour the neuropathy-associated LOS gene
cluster types A, B or C. Using primers based on the C. coli
RM2228 LOS gene cluster, we amplified the LOS locus of
GB50, but we could not amplify the LOS locus of
664H2004. Complete sequencing of the novel GB50 LOS
gene cluster revealed 12 open reading frames (ORFs) that
included five putative glycosyltransferases and a few ORFs
seemingly unrelated to LOS biosynthesis (Table 1).
The LOS of C. coli strain GB50 did not bind cholera
toxin, hence, the presence of a GM1-like ganglioside mimic
could be excluded. The acute phase pre-treatment serum
from patient GB50 showed a high level of IgG activity to
the LOS from the GB50 strain (Table 2). This activity was
significantly higher than in the serum from ten healthy
blood donors. In addition, in the serum from patient GB50,
IgM activity was found for this LOS, although it was less
than the IgG activity. Some of the healthy blood donors
also showed this elevated level of IgM. Probing the LOS
with six specific monoclonal anti-ganglioside antibodies
(DG-1, DG-2, TBG-3, EG-7, EG-3 and EG-1) did not reveal
any reactivity. These monoclonal antibodies were raised by
immunisation with C. jejuni LOS and bound to various
(combinations of) gangliosides (Table 2). Interestingly,
regular mass spectrometry analysis on O-deacylated C. coli
LOS [1] did not reveal a structural overlap between this LOS
and the previously determined C. jejuni LOS structures. It
appeared that the GB50 LOS did not contain sialic acid based
on MS/MS analysis. The LOS from the 664H2004 strain was
shown to contain di-NeuAc based on MS/MS analysis.
The serum from patient GB50 was tested in a stand-
ardised enzyme-linked immunosorbent assay (ELISA) for
the detection of antibodies to the gangliosides GM1, GM2,
GD1a, GD1b, GD3 and GQ1b [8]. Serum was positive for
IgG, IgM and IgA antibodies to the gangliosides GM1 and,
to a lesser extent, to GD1b (Table 2). These gangliosides
share the terminal Gal(β1–3)GalNac to which these anti-
bodies are probably directed. Accordingly, the serum from
this patient contained high IgG, IgM and IgA activity to the
non-ganglioside glycolipid asialo-GM1, which has the
same terminal disaccharide. Such a structure, however,
was not identified in the LOS of the C. coli isolate from this
patient. This suggests that this patient might have been co-
infected with another organism expressing a GM1 mimic,
possibly a C. jejuni strain, responsible for a non-GBS-
related induction of a cross-reactive antibody response to
GM1. In inhibition ELISA experiments, anti-GM1 IgG
activity in 1:400 dilutions of serum from GB50 was not
reduced by LOS from this strain in concentrations of up to
Fig. 1 Amplified fragment length polymorphism (AFLP) analysis of the two Campylobacter coli strains isolated from patients GB50 and
664H2004. Note that, despite their diverse geographic origins, these strains cluster, but clearly fall within the C. coli cluster
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200 μg/ml, demonstrating that these antibodies do not cross-
react with the LOS from the C. coli isolate from the patient.
In control studies, this antibody activity was reduced to a
level of less than 5% by pre-incubation with LOS from a C.
jejuni isolate GB2 from another GBS patient, in which
mimicry with GM1 was previously demonstrated by MS [9].
Overall, we have comprehensively characterised two C.
coli strains isolated from GBS patients with a variety of
state of the art technologies. One strain (664H2004)
harboured disialylated LOS, but, unfortunately, no serum
was available to measure either anti-ganglioside or anti-
LOS antibodies in the GBS patient herself. The other strain
from the Dutch patient (GB50) had non-sialylated LOS,
which showed no binding to cholera toxin or to mono-
clonals specific for several gangliosides. However, the
serum from patient GB50 from which C. jejuni GB50 was
isolated did contain antibodies to the LOS from this strain,
indicating that this infection led to a specific immune
response to C. coli strain GB50. The role of this immune
response in the pathogenesis of GBS is currently unknown,
although other examples of GBS patients infected with non-
ganglioside mimicking strains of C. jejuni have been
described [10]. The serum from GB50, however, also
contained antibodies to GM1 and GD1a, which do not
Table 2 Characterisation of Campylobacter coli strains isolated from two patients with Guillain-Barré syndrome (GBS)
GB50 664H2004
Genotyping strains
LOS biosynthesis cluster Non-typable (no sialic acid incorporating enzymes encoded) Class B (does contain Cst2)
Structure of LOS (MS/MS analysis)
Presence sialic acids − Di-NeuAc
Binding studies with LOS
Cholera toxin B-subunit − −
Anti-ganglioside mAbs1 − −
IgG in serum patient GB50 ++2 −
IgM in serum patient GB50 +2 −
Serum anti-ganglioside antibodies3
IgG GM1 (6400), GD1b (400) n.a.
IgM GM1 (800), GD1b (200) n.a.
IgA GM1 (200), GD1b (100) n.a.
Cross-reactivity serum antibodies
Anti-GM1 IgG in serum GB504 − −
n.a.; not available
1Monoclonal antibodies DG-1 (to GM1), DG-2 (to GM1/GD1b/GA1), TBG-3 (to GD1a), EG-7 (to GD1b), EG-3 (to GQ1b) and EG-1 (to GT1a/
GQ1b)
2 Significantly higher than antibody activity to this LOS in serum from ten healthy blood donors
3 Serum IgG, IgM and IgA tested to GM1, GM2, GD1a, GD1b, GD3 and GQ1b
4 The cross-reactivity of 1:400 diluted serum anti-GM1 IgG antibodies from patient GB50 to LOS from C. coli GB50 and 664H2004 were
determined by inhibition enzyme-linked immunosorbent assay (ELISA)
Table 1 Information on the lipo-oligosaccharide (LOS) gene cluster for strain GB50 (GenBank accession number EU374214)
Source sequence 1...11261
Nucleotide position Gene orientation Gene annotation Putative gene function
1–108 + waaC Heptosyltransferase I
101–988 + htrB Lipid A biosynthesis acyltransferase
985–2538 + orf3 Putative glycosyltransferase
2535–3587 + orf4 Putative glycosyltransferase
3584–4783 − orf5 Putative glycosyltransferase
4911–6215 + orf6 Putative CDP-glycerol:polyglycerophosphatase
6212–7246 + orf7 Hypothetical protein
7316–8335 + orf8 Transposase-like insertion element
8214–8924 + orf9 Hypothetical protein
8917–9837 + orf10 Putative DNA methyltransferase
10021–10437 + orf11 Putative glycerol-3-phosphate cytidyltransferase.
10456–11261 − waaV Putative glycosyltransferase
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cross-react with LOS from GB50, as expected, although
they do cross-react with LOS from a C. jejuni with a known
GM1 mimic. These serological findings in patient GB50
strongly suggest that this patient was infected with at least
two micro-organisms, one of which induced the anti-
ganglioside antibodies leading to GBS (possibly a C. jejuni
strain), and C. coli, which also induced an immune
response, but probably did not trigger GBS.
In summary, we could not produce any evidence that
molecular mimicry plays a role in the pathogenesis of GBS
that is preceded by a C. coli infection. It is still not clear
whether C. coli isolated from the faeces of GBS patients
can play a role in the development of GBS. Additional GBS
patients and their C. coli strains need to be reported and
characterised in detail in order to better understand the
pathogenesis of GBS in these patients.
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